Roche Recalls Viracept - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Roche Recalls Viracept

ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Basel, Switzerland (June 6)—Roche, in an agreement with the European Medicines Agency (EMEA, London) and the Swiss Agency for Therapeutic Products (Swissmedic, Bern, Switzerland), recalled all batches of “Viracept” (nelfinavir) powder and tablets in Europe and some other regions of the world.

Viracept is a protease inhibitor supplied by Roche outside the United States and Canada. The United States, Canada, and Japan are not affected by the recall.

Roche received several reports that some batches of Viracept 250-mg tablets had a strange odor. A chemical analysis of the affected tablets showed they contained higher than normal levels of methane sulfonic acid ethylester.

Ethyl mesylate is a genotoxic substance, according to EMEA. “The level of risk to patients resulting from this contamination is difficult to measure, and is currently under further evaluation,” said EMEA in a press release.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here